日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Giardia intestinalis Glucosamine-6-phosphate isomerase 2 (GPI2) CSB-YP009631GFW
CSB-EP009631GFW
CSB-BP009631GFW
CSB-MP009631GFW
CSB-EP009631GFW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Dog C-X-C chemokine receptor type 2 (CXCR2), partial CSB-YP011673DO1
CSB-EP011673DO1
CSB-BP011673DO1
CSB-MP011673DO1
CSB-EP011673DO1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ornithorhynchus anatinus Amelogenin (AMEL) CSB-YP001664OEX
CSB-EP001664OEX
CSB-BP001664OEX
CSB-MP001664OEX
CSB-EP001664OEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Suncus murinus Progonadoliberin-2 (GNRH2) CSB-YP009636FPS
CSB-EP009636FPS
CSB-BP009636FPS
CSB-MP009636FPS
CSB-EP009636FPS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pygathrix bieti C-C chemokine receptor type 5 (CCR5), partial CSB-YP004844FHN1
CSB-EP004844FHN1
CSB-BP004844FHN1
CSB-MP004844FHN1
CSB-EP004844FHN1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhinopithecus avunculus C-C chemokine receptor type 5 (CCR5), partial CSB-YP004844RKF1
CSB-EP004844RKF1
CSB-BP004844RKF1
CSB-MP004844RKF1
CSB-EP004844RKF1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cytochrome c oxidase subunit 1 (COI), partial CSB-YP015072EWO
CSB-EP015072EWO
CSB-BP015072EWO
CSB-MP015072EWO
CSB-EP015072EWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Connochaetes gnou Cytochrome b (MT-CYB), partial CSB-YP015075DVQ
CSB-EP015075DVQ
CSB-BP015075DVQ
CSB-MP015075DVQ
CSB-EP015075DVQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Madoqua kirkii Cytochrome b (MT-CYB), partial CSB-YP015075MPL
CSB-EP015075MPL
CSB-BP015075MPL
CSB-MP015075MPL
CSB-EP015075MPL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Eulemur macaco macaco Cytochrome b (MT-CYB), partial CSB-YP015075EPG
CSB-EP015075EPG
CSB-BP015075EPG
CSB-MP015075EPG
CSB-EP015075EPG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhipicephalus sanguineus ATP synthase protein 8 (MT-ATP8), partial CSB-YP015071RKI
CSB-EP015071RKI
CSB-BP015071RKI
CSB-MP015071RKI
CSB-EP015071RKI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhipicephalus sanguineus NADH-ubiquinone oxidoreductase chain 4L (ND4L), partial CSB-YP015080RKI1
CSB-EP015080RKI1
CSB-BP015080RKI1
CSB-MP015080RKI1
CSB-EP015080RKI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant NADH-ubiquinone oxidoreductase chain 3 (NAD3), partial CSB-YP015078EXV1
CSB-EP015078EXV1
CSB-BP015078EXV1
CSB-MP015078EXV1
CSB-EP015078EXV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cenocepacia tRNA pseudouridine synthase A (truA) CSB-YP019086BXQ
CSB-EP019086BXQ
CSB-BP019086BXQ
CSB-MP019086BXQ
CSB-EP019086BXQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cenocepacia Elongation factor Ts (tsf) CSB-YP025124BXQ
CSB-EP025124BXQ
CSB-BP025124BXQ
CSB-MP025124BXQ
CSB-EP025124BXQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cenocepacia GMP synthase [glutamine-hydrolyzing] (guaA), partial CSB-YP009582BXQ
CSB-EP009582BXQ
CSB-BP009582BXQ
CSB-MP009582BXQ
CSB-EP009582BXQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 ATP synthase subunit beta (atpD) CSB-YP002350YAX
CSB-EP002350YAX
CSB-BP002350YAX
CSB-MP002350YAX
CSB-EP002350YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 ATP synthase subunit delta (atpH) CSB-YP002355YAX
CSB-EP002355YAX
CSB-BP002355YAX
CSB-MP002355YAX
CSB-EP002355YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Peptide chain release factor 1 (prfA) CSB-YP015197YAX
CSB-EP015197YAX
CSB-BP015197YAX
CSB-MP015197YAX
CSB-EP015197YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Yersinia pseudotuberculosis serotype O:3 Glucose-6-phosphate isomerase (pgi), partial CSB-YP009717YAX
CSB-EP009717YAX
CSB-BP009717YAX
CSB-MP009717YAX
CSB-EP009717YAX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×